v3.25.1
Consolidated Statements of Changes in Members' Equity and Stockholders' Equity - USD ($)
$ in Thousands
Total
Class A [Member]
Class B [Member]
Members' Equity [Member]
Common Stock [Member]
Class A [Member]
Common Stock [Member]
Class B [Member]
Additional Paid-in capital [Member]
Retained Earnings [Member]
Non-Controlling Interests [Member]
Beginning Balance at Dec. 31, 2022 $ 75,929     $ 42,729         $ 33,200
Contributions 889               889
Non-cash equity contribution 225               225
Net income 37,720     23,902         13,818
Distributions (54,904)     (38,422)         (16,482)
Net income (loss) attributable to non-controlling interest 13,818                
Ending Balance at Dec. 31, 2023 59,859     28,209         31,650
Contributions 428               428
Net income 7,095     2,786         4,309
Distributions (10,809)     (7,130)         (3,679)
Net income (loss) attributable to non-controlling interest 4,309                
Ending Balance at Mar. 31, 2024 56,573     23,865         32,708
Beginning Balance at Dec. 31, 2023 59,859     28,209         31,650
Net income (71,033)                
Net income prior to Corporate Reorganization 39,110     22,760         16,350
Contributions prior to Corporate Reorganization 2,107               2,107
Distributions prior to Corporate Reorganization (50,329)     (36,050)         (14,279)
Non-cash equity contribution prior to Corporate Reorganization 4,989               4,989
Conversion of non-controlling interest into Guardian Pharmacy, LLC common units       34,169         (34,169)
Conversion of Restricted Interest Unit awards into Guardian Pharmacy, LLC common units 142,498     142,498          
Conversion of Class B Common Stock to Class A Common Stock (Shares)           54,094,232      
Conversion of Class B Common Stock to Class A Common Stock       $ (191,586)   $ 54 $ 9,185 $ 182,347  
Issuance of Class A common stock, net of costs (Shares)         9,200,000        
Issuance of Class A common stock, net of costs 106,762       $ 9   106,753    
Payments to Class B common stock stockholders of $1.02 per share (55,176)             (55,176)  
Recognition of deferred tax asset, net from Corporate Reorganization 5,973           5,973    
Net income (loss) attributable to Guardian Pharmacy Services, Inc. (110,047) $ (16,261) $ (93,786)         (110,047)  
Share-based compensation forfeitures (Shares)           (7,074)      
Net income (loss) attributable to non-controlling interest 16,254                
Share-based compensation forfeitures (1)           (1)    
Net income (loss) attributable to non-controlling interest subsequent to Corporate Reorganization (96)               (96)
Contributions Subsequent To Corporate Reorganization 651               651
Non-cash equity contribution subsequent to Corporate Reorganization 286               286
Distributions Subsequent To Corporate Reorganization (184)               (184)
Equity-based compensation subsequent to Corporate Reorganization 3,574           3,574    
Ending Balance at Dec. 31, 2024 149,976       $ 9 $ 54 125,484 17,124 7,305
Ending Balance (Shares) at Dec. 31, 2024         9,200,000 54,087,158      
Contributions 135               135
Net income 9,273                
Distributions (135)               (135)
Conversion of Class B Common Stock to Class A Common Stock (Shares)         13,519,946 (13,519,946)      
Conversion of Class B Common Stock to Class A Common Stock         $ 14 $ (14)      
Net income (loss) attributable to Guardian Pharmacy Services, Inc. 9,448 $ 1,490 $ 7,958         9,448  
Share-based compensation forfeitures (Shares)           (516)      
Net income (loss) attributable to non-controlling interest (175)               (175)
Share-based compensation forfeitures (1)           (1)    
Share-based compensation expense 3,969           3,969    
Ending Balance at Mar. 31, 2025 $ 163,217       $ 23 $ 40 $ 129,452 $ 26,572 $ 7,130
Ending Balance (Shares) at Mar. 31, 2025         22,719,946 40,566,696